Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Up 6.7 %

Shares of Brooklyn ImmunoTherapeutics stock opened at $0.31 on Tuesday. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10. The business’s 50 day moving average is $0.34 and its 200-day moving average is $0.89. The stock has a market cap of $18.07 million, a P/E ratio of -0.14 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.